Cullinan Therapeutics, Inc. financial data

Symbol
CGEM on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
One Main Street, Suite 1350, Cambridge, MA
Fiscal year end
December 31
Former names
Cullinan Oncology, Inc. (to 4/2/2024), Cullinan Management, Inc. (to 2/22/2021), Cullinan Oncology, LLC (to 1/6/2021)
Latest financial report
10-Q - Q3 2024 - Nov 7, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2.25K % +11.6%
Debt-to-equity 4.83 % -7.48%
Return On Equity -26.5 % +15.5%
Return On Assets -25.3 % +15.2%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 58.2M shares +36.1%
Common Stock, Shares, Outstanding 58.1M shares +36%
Entity Public Float 374M USD -0.4%
Common Stock, Value, Issued 6K USD +50%
Weighted Average Number of Shares Outstanding, Basic 58.3M shares +36.5%
Weighted Average Number of Shares Outstanding, Diluted 58.3M shares +36.5%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 0 USD -100%
Research and Development Expense 137M USD +1.95%
General and Administrative Expense 50.1M USD +16.1%
Operating Income (Loss) -187M USD -5.13%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -169M USD -212%
Income Tax Expense (Benefit) -14.1M USD -134%
Net Income (Loss) Attributable to Parent -144M USD +8.07%
Earnings Per Share, Basic -2.84 USD/shares +24.9%
Earnings Per Share, Diluted -2.84 USD/shares +23.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 102M USD +57.4%
Cash, Cash Equivalents, and Short-term Investments 578M USD
Other Assets, Current 3.9M USD
Assets, Current 592M USD +24.2%
Other Long-term Investments 15.5M USD -49.5%
Property, Plant and Equipment, Net 760K USD -28.7%
Operating Lease, Right-of-Use Asset 2.02M USD -31%
Other Assets, Noncurrent 460K USD +0.22%
Assets 653M USD +32%
Accounts Payable, Current 2.12M USD +122%
Accrued Liabilities, Current 20.8M USD -0.55%
Liabilities, Current 24.2M USD +3.24%
Operating Lease, Liability, Noncurrent 1.19M USD -51.4%
Liabilities 25.4M USD -1.92%
Accumulated Other Comprehensive Income (Loss), Net of Tax 970K USD
Retained Earnings (Accumulated Deficit) -321M USD -81.1%
Stockholders' Equity Attributable to Parent 628M USD +33.9%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 628M USD +33.9%
Liabilities and Equity 653M USD +32%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -38.2M USD +25%
Net Cash Provided by (Used in) Financing Activities 1.09M USD -39.4%
Net Cash Provided by (Used in) Investing Activities 13M USD -14.7%
Common Stock, Shares Authorized 150M shares 0%
Common Stock, Shares, Issued 58.1M shares +36%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Deferred Tax Assets, Valuation Allowance 87.4M USD +86.8%
Deferred Tax Assets, Gross 88.3M USD +83.3%
Operating Lease, Liability 2.45M USD -38.7%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -142M USD +7.66%
Lessee, Operating Lease, Liability, to be Paid 2.69M USD -41.2%
Property, Plant and Equipment, Gross 1.34M USD +2.45%
Operating Lease, Liability, Current 1.26M USD -18.7%
Lessee, Operating Lease, Liability, to be Paid, Year Two 871K USD -40.4%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.46M USD -15.9%
Operating Lease, Weighted Average Discount Rate, Percent 0.11 pure 0%
Deferred Income Tax Expense (Benefit) 0 USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 243K USD -58.2%
Lessee, Operating Lease, Liability, to be Paid, Year Three 872K USD -40.3%
Deferred Tax Assets, Operating Loss Carryforwards 14.4M USD +37.1%
Preferred Stock, Shares Issued 648K shares 0%
Preferred Stock, Shares Authorized 10M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 872K USD
Preferred Stock, Shares Outstanding 648K shares 0%
Depreciation, Depletion and Amortization 76K USD +5.56%
Deferred Tax Assets, Net of Valuation Allowance 914K USD -34.8%
Share-based Payment Arrangement, Expense 35.7M USD +17.3%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%